Efficacy and Safety of FOLFIRI With Durvalumab With or Without Tremelimumab as the Second-Line Treatment in Patients With Advanced Gastric/GEJ Adenocarcinoma
Findings from the PRODIGE 59-FFCD 1707-DURIGAST study
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Findings from the PRODIGE 59-FFCD 1707-DURIGAST study
Slides and Webcasts from all ESMO Advanced Courses are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.